On March 5, the FDA approved Spravato (esketamine) nasal spray, in conjunction with an oral antidepressant, for treatment-resistant depression, but it’s only available through a restricted distribution system.
Read more via U.S. Food and Drug Administration.
Get your free access to the exclusive newsletter of American Nurse Journal and gain insights for your nursing practice.
*By submitting your e-mail, you are opting in to receiving information from Healthcom Media and Affiliates. The details, including your email address/mobile number, may be used to keep you informed about future products and services.
